Business Wire

Enry's Island S.p.A. Becomes the First and Only Venture Builder in the World Listed on a Stock Exchange, After a €20M Round A

27.7.2023 20:46:00 EEST | Business Wire | Press release

Share

Enry's Island S.p.A. is pleased to announce that it has successfully finalised its listing on the Vienna Stock Exchange - MTF, supported by PwC Austria, becoming the first and only Venture Builder in the world listed on a Stock Exchange.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230727222549/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Luigi Valerio Rinaldi Founder & Chairman of Enry's Island S.p.A. (Graphic: Business Wire)

“We are really proud of this incredible milestone,” says Luigi Valerio Rinaldi, Chairman & CEO of Enry's Island, “made possible thanks to the trust of internationally qualified operators, such as PwC Austria, supporting us in the Financial Due Diligence and Valuation phase, to successfully finalise the listing process on the Vienna Stock Exchange.

The listing on the VSE consolidates the internationality of the equity story and the scale-up phase of Enry's Island, one of the most interesting and innovative ecosystems on the global VC scene, explained by the following highlights:

  • a distributed corporate architecture, which includes Enry’s Island and its 5 Local Companies (distributed in UK, US, Africa, Italy), with an average of 30 Companies (including portfolio startups).
  • a unique holistic 3-layered framework, made of:
    • Business Layer: Enry's Model™ patented methodology, which later became the subject of economics manuals published by McGraw-Hill
    • Software Layer: HUI.land, a Super-App Saas used by each of the companies and stakeholders of the ecosystem, through which to manage every business function and process in the entire dealflow (from origination to fundraising)
    • Space Layer: Rinascimento5, the first phygital distributed coworking in the world, through which the community of Enry's Island can operate fully remotely;
  • an incredible growth in the quantity and quality of its economic, financial and equity indicators (increase in turnover of x2 in 2022 compared to 2021, which also continues in the first half of 2023, in which the turnover of 2022 has already been reached)
  • a large trust of qualified international investors, such as LDA Capital, a Los Angeles based fund with $11B in portfolio, which closed a €20M A Round with Enry's Island;
  • a success rate of its portfolio companies of 95% against the market average of 5%;
  • one of the first operators (not only among venture builders) to build its own headquarters in the metaverse, as early as 2021 and to have organised phygital investor days in the metaverse.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Investor relations:
emmanuelle.deba@enrysisland.com
0039 393 9774542

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye